Individuals infected but undiagnosed with HIV and diagnosed but not yet in medical care accounted for more than 90% of the estimated 45,000 United States HIV transmissions in 2009.

Liver disease and tuberculosis were common in a cohort of adult South African patients with HIV, according to data from a retrospective John Hopkins study.

An NIH-led safety and efficacy trial of an experimental HIV vaccine regimen has begun in SA, with experimental vaccines from Sanofi Pasteur and Novartis.

Scientists from the Scripps Research Institute have announced the creation of a novel drug candidate that is so potent and universally effective against HIV, it might work as part of an unconventional vaccine.

Two studies using interferon-free drug regimens for HIV patients with hepatitis C virus (HCV) resulted in high rates of sustained virologic response, which is a lack of detectable HCV RNA at least 12 weeks after completion of treatment.